SBI-101

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameSBI-101

Drug Alias NameSBI101SBI-101

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cells modulatorsImmunosuppressants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acute Kidney InjurySepsis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSentien Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSentien Biotechnologies Inc

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Acute Kidney InjurySepsis

Other Information

ATC CodeN/A